Drug intelligence / Profile preview

bupivacaine + dexmedetomidine + lidocaine

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Epidural, Perineural, Infiltration

Overview

This is a combination of three drugs used for local and regional anesthesia. The combination includes bupivacaine (a long-acting local anesthetic), dexmedetomidine (an alpha-2 adrenergic receptor agonist), and lidocaine (a fast-acting local anesthetic). Studies suggest this combination provides enhanced and prolonged anesthetic and analgesic effects compared to individual components. The combination appears to offer advantages in terms of onset time, duration of sensory and motor blockade, and reduced incidence of nociception during surgical procedures.

Other names: bupivacainedexmedetomidinelignocainelidocaine

Targets

NaV (Voltage-gated sodium channels)ADRA2A (α2A)

Beyond the preview

Go deeper on bupivacaine + dexmedetomidine + lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupivacaine + dexmedetomidine + lidocaine.

Explore the full profile